Levi & Korsinsky, LLP Issues Statement on Class Action Lawsuit Against Novo Nordisk A/S

New York, Jan. 24, 2025 (GLOBE NEWSWIRE) —

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) between November 2, 2022 to December 19, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Changyeon Moon v.

Levi & Korsinsky, LLP has recently issued a statement regarding a class action lawsuit filed against Novo Nordisk A/S. The lawsuit, Changyeon Moon v. Novo Nordisk A/S, concerns the period between November 2, 2022, and December 19, 2024, during which individuals or entities who purchased or acquired securities of the company may be affected.

The lawsuit alleges certain violations of securities laws and seeks to recover damages on behalf of affected investors. While the specifics of the allegations have not been disclosed, the lawsuit suggests that there may have been improprieties or misleading information provided by Novo Nordisk A/S during the specified timeframe.

Investors who were involved in transactions related to Novo Nordisk A/S during the mentioned period should take note of this lawsuit and consider their legal options. It is essential for affected individuals or entities to stay informed about the developments in this case and consult with legal counsel to understand their rights and potential courses of action.

Effects on Individuals

For individuals who purchased or acquired securities of Novo Nordisk A/S between November 2, 2022, and December 19, 2024, the class action lawsuit may have significant implications. Depending on the outcome of the lawsuit, affected investors may be entitled to recover damages if the allegations are proven true. It is crucial for these individuals to monitor the progress of the case and seek legal advice to protect their interests.

Effects on the World

The class action lawsuit against Novo Nordisk A/S could have broader implications for the financial market and corporate governance on a global scale. If the allegations of securities law violations are substantiated, it could impact investor confidence in the company and the pharmaceutical industry as a whole. The outcome of this case may also influence regulatory measures and compliance standards within the healthcare sector.

Conclusion

In conclusion, the class action lawsuit against Novo Nordisk A/S serves as a reminder of the importance of transparency and integrity in corporate practices. Investors should remain vigilant and informed about legal proceedings that may affect their investments. As the case unfolds, it will be essential for all parties involved to seek clarity and justice in accordance with the law.